학술논문
A booster dose of SARS-COV-2 vaccine improves suboptimal seroconversion rates in patients with inflammatory bowel disease. Results of a prospective multicenter study of GETECCU (VACOVEII study)
Document Type
Article
Author
Casas Deza, Diego; Julián Gomara, Ana Belén; Caudevilla Biota, Eva; Beltrán, Belén; Domènech, Eugeni; Gutiérrez Casbas, Ana; Mañosa, Miriam; Zabana, Yamile; Roc Alfaro, Lourdes; Valverde Romero, Emilio; García González, Elena; Sicilia, Beatriz; Laredo, Viviana; Alcalá Escriche, Maria José; Madero Velázquez, Lucia; Ferreiro-Iglesias, Rocío; Palmero Pérez, Antonia; Calafat, Margalida; Rubio Iturria, Saioa; Moraleja Yudego, Irene; Ber Nieto, Yolanda; García Mateo, Sandra; P. Gisbert, Javier; Vicente Lidón, Raquel; Arias, Lara; Alfambra, Erika; Doñate Borao, Ana Belén; Peña González, Elena; Corsino Roche, Pilar; Vicuña Arregui, Miren; Elorza, Ainara; Domínguez Cajal, Manuel; Chaparro, María; Barreiro-de Acosta, Manuel; García-López, Santiago
Source
Gastroenterología y Hepatología (ScienceDirect); 20240101, Issue: Preprints
Subject
Language
ISSN
02105705
Abstract
The response to SARS-CoV-2 vaccination decreases in inflammatory bowel disease (IBD) patients, specially under anti-TNF treatment. However, data on medium-term effectiveness are limited, specially using new recommended seroconversion rate (>260BAU/mL). Our aim was to evaluate the 6-month>260 BAU-seroconversion rate after full vaccination and after booster-dose.